EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Janus Kinase Inhibitors During Pregnancy and Adverse Drug Reactions: A Pharmacovigilance Disproportionality Analysis in V igi B ase

Nazanin Abolhassani iD, Roberta Noseda iD, Kim Dao iD, François R Girardin iD, Francesca Bedussi iD, Alessandro Ceschi iD, Alice Panchaud iD, Ursula Winterfeld iD

Clinical and Translational Science · 2025

DOI: 10.1111/cts.70429 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical and Translational Science, 2025. Verfasst von Nazanin Abolhassani und 7 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Primary Health Care (BIHAM), University of Bern, Bern, Switzerland. Hauptthemen laut MEDLINE: Janus Kinase Inhibitors, Pregnancy Complications, Drug-Related Side Effects and Adverse Reactions. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Janus kinase inhibitors (JAKIs) are immunomodulatory drugs used for autoimmune and inflammatory conditions. Their potential impact on pregnancy and fetal development remains a concern due to placental transfer and potential disruption of cytokine and growth factor signaling, with limited human data. This study analyzed VigiBase, the World Health Organization global pharmacovigilance database of individual case safety reports (ICSRs), to assess signals of disproportionate reporting (SDRs) for pregnancy‐related adverse drug reactions (ADRs) reported with systemic JAKIs, including abrocitinib, baricitinib, deucravacitinib, fedratinib, filgotinib, itacitinib, momelotinib, pacritinib, peficitinib, ritlecitinib, ruxolitinib, tofacitinib, and upadacitinib. As of May 26, 2024, 163 ICSRs met inclusion criteria, mainly from North America (41.7%) and Europe (39.3%). The most frequently reported JAKIs were tofacitinib (44.8%) and upadacitinib (34.4%), primarily indicated for rheumatoid arthritis (29.4%). Among 213 pregnancy‐related ADRs, spontaneous abortion was the most frequently reported event (47.9%) without representing an SDR compared with other drugs in the database (reporting odds ratio [ROR] 0.37, 95% confidence interval [CI] 0.30–0.46). Congenital anomalies were reported in 16.0% of ICSRs (43 events), but no specific organ‐related patterns were identified. Prematurity occurred in 9.2% of ICSRs, without SDR compared to the full database (ROR 0.07, 95% CI 0.04–0.11). Current pharmacovigilance data from VigiBase do not indicate SDRs for spontaneous abortion or prematurity following JAKI exposure during pregnancy. Findings should be interpreted cautiously given the limitations of spontaneous reporting systems and the exploratory nature of the analysis. Further studies are needed to better characterize the JAKI safety in pregnancy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Janus Kinase InhibitorsPregnancy ComplicationsDrug-Related Side Effects and Adverse ReactionsHumansFemalePregnancyPharmacovigilanceAdverse Drug Reaction Reporting SystemsAdultDatabases, FactualYoung Adult

Stichwörter der Autor:innen

JAK inhibitorsVigiBasedisproportionalitypharmacovigilancepregnancy

Substanzen

Janus Kinase Inhibitors

Autor:innen und Institutionen

  • Institute of Primary Health Care (BIHAM), University of Bern, Bern, Switzerland.
  • Division of Clinical Pharmacology and Toxicology, Institute of Pharmacological Sciences of Southern Switzerland, Ente Ospedaliero Cantonale, Lugano, Switzerland.
  • Swiss Teratogen Information Service (STIS) and Clinical Pharmacology Service, Centre Hospitalier Universitaire Vaudois (CHUV) and University of Lausanne, Lausanne, Switzerland.
  • Clinical Trial Unit, Ente Ospedaliero Cantonale, Lugano, Switzerland.
  • Faculty of Biomedical Sciences, Università della Svizzera Italiana, Lugano, Switzerland.
  • Service of Pharmacy, Centre Hospitalier Universitaire Vaudois (CHUV), Lausanne, Switzerland.

ORCID-Profile: Nazanin Abolhassani, Roberta Noseda, Kim Dao, François R Girardin, Francesca Bedussi, Alessandro Ceschi, Alice Panchaud, Ursula Winterfeld

Zitieren

APA

Abolhassani, N., Noseda, R., Dao, K., Girardin, F. R., Bedussi, F., Ceschi, A., Panchaud, A., & Winterfeld, U. (2025). Janus Kinase Inhibitors During Pregnancy and Adverse Drug Reactions: A Pharmacovigilance Disproportionality Analysis in V igi B ase. Clinical and Translational Science. https://doi.org/10.1111/cts.70429

Vancouver

Abolhassani N, Noseda R, Dao K, Girardin FR, Bedussi F, Ceschi A, et al. Janus Kinase Inhibitors During Pregnancy and Adverse Drug Reactions: A Pharmacovigilance Disproportionality Analysis in V igi B ase. Clinical and Translational Science. 2025. doi:10.1111/cts.70429

BibTeX
@article{Abolhassani2025,
  author = {Abolhassani, Nazanin and Noseda, Roberta and Dao, Kim and Girardin, François R and Bedussi, Francesca and Ceschi, Alessandro and Panchaud, Alice and Winterfeld, Ursula},
  title = {Janus Kinase Inhibitors During Pregnancy and Adverse Drug Reactions: A Pharmacovigilance Disproportionality Analysis in V igi B ase},
  journal = {Clinical and Translational Science},
  year = {2025},
  doi = {10.1111/cts.70429}
}
Kostenlos starten →